NCT02633150

Brief Summary

Obesity, chronic disease, is a real public health problem because of its high prevalence but also because of the high risk of complications, including insulin resistance (IR) and type 2 diabetes (T2D). The mechanisms involved in the development of IR are not well known. Oxidative stress and inflammation induced by food overload could be the initiators IR mechanisms in skeletal muscle, responsible for the use of nearly 80% glucose in response to insulin and therefore plays a major role in the regulation of glucose metabolism. Thus, an increase in ROS (Reactive Oxygen Species), markers of oxidative stress and chronic low-grade inflammation have been demonstrated in subjects with obesity, the latter decreasing in weight loss. Therapeutically, loosing weight is still very difficult these days, because of the complexity of this chronic disease. Thus, it is well established that restrictive diets to expose weight rebound, dramatic medically as in human terms for these patients. Support for physical activity is also difficult because of reduced mobility in patients, refer to the lack of motivation among some. Finally, investigators have no treatment "against-obesity" who have demonstrated a benefit / risk enough to be used routinely. It is therefore essential to seek other means of struggle against the IR, see help in weight loss. In parallel, it is well established that the consumption of certain antioxidants, including polyphenols (PP) grape as extracts and whole foods, modulates favorably several pathways responsible for the development of IR in cell models animals. The results of antioxidants supplementation in humans are few and controversial. However, most supplementation studies in human used a PP, Resveratrol at supra nutritional doses (ie not compatible with a balanced diet of fruits and vegetables). In a previous study, investigators tested the interest of a supplementation with red grape PP nutritional doses in healthy subjects with metabolic risk (overweight subjects and related to the first degree of T2DM patients) on IR hyperinsulinemic euglycemic clamp measured. During this study, the PP have prevented the central mechanisms of muscle IR that are oxidative stress and mitochondrial dysfunction induced by a load fructose. For this project, investigators propose to test the effect of a red grape PP supplementation at nutritional doses for 8 weeks on IR and weight loss in 30 obese insulin resistant. This is a double-blind randomized placebo-controlled. This supplementation will be associated with a standard support for their obesity performed routinely in the Nutrition and Diabetes unit. Specific inclusion criteria: Female or male nondiabetic 50-65 years, BMI\> 30 kg / m2 and with a HOMA\> 3. The main objective is to test whether supplementation PP improves systemic insulin sensitivity (GIR: rate glucose infusion) measured by hyperinsulinemic-euglycemic clamp (gold standard for measuring insulin sensitivity) in insulin-resistant obese subjects. Secondary objectives are to:

  • Test whether supplementation PP improves insulin sensitivity to tissue (fat and muscle) and compare the response to supplementation in these two tissues.
  • Determining the cellular and molecular mechanisms involved in improving IR: regulation of inflammation, oxidative stress.
  • Determine whether supplementation PP optimizes weight reduction compared to a standard single support. NSN: The number of subjects required was evaluated from our previous work (2013 Hokayem et al.) Whose main objective was to assess the impact of PD versus placebo in first degree relatives of patients with diabetes type 2. Under a bilateral alternative hypothesis of a nonparametric test (Mann-Whitney), 1: 1 ratio, a power of 80% and an alpha risk of 0.05, the number of subjects was estimated at 15 per group. Methodology: Anthropometric measurements, assessment of body composition (DEXA) system application characterization (metabolism, inflammation, oxidative stress, adipokines and insulin sensitivity: clamp hyperinsulinemic-euglycemic, lipopolysaccharides: LPS) / tissue characterization (biopsies of skeletal muscle and tissue adipose): insulin sensitivity, inflammation, oxidative stress, gene regulation (sirt1), mitochondrial activity / cell characterization (adipocyte precursor and muscle) insulin sensitivity, inflammation, oxidative stress, sirt1. Investigators hope to demonstrate that a non-pharmacological treatment based on nutritional doses of PP supplementation can improve insulin sensitivity in insulin-resistant obese patients, refer to optimize weight loss compared to a standardized management of obesity and determine the mechanisms involved.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for not_applicable obesity

Timeline
Completed

Started Oct 2015

Longer than P75 for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 6, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 9, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 17, 2015

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2020

Completed
Last Updated

December 21, 2021

Status Verified

December 1, 2021

Enrollment Period

4.7 years

First QC Date

December 9, 2015

Last Update Submit

December 20, 2021

Conditions

Keywords

Obesityinsulinoresistantmenopausal womenpolyphenol

Outcome Measures

Primary Outcomes (1)

  • Measure of systemic insulin sensitivity (estimated by GIR :rate glucose infusion) measured by hyperinsulinemic-euglycemic clamp

    GIR change after 8 weeks of supplementation

    8 weeks after supplementation

Secondary Outcomes (2)

  • Measure of insulin sensitivity to tissue (fat and muscle by measure ratio phosphoAKT/AKT measured by Western BLOT) before and after the supplementation

    8 weeks after supplementation

  • Measure of systemic concentration (by Multiplex)

    8 weeks after supplementation

Study Arms (2)

Polyphenol

EXPERIMENTAL

red grapes polyphenol supplementation on metabolic parameters in obese insulinoresistant subjects

Other: Supplementation with red grapes polyphenol

Placebo

PLACEBO COMPARATOR

Placebo supplementation on metabolic parameters in obese insulinoresistant subjects

Other: Supplementation with red grapes polyphenol

Interventions

Eligibility Criteria

Age50 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female or Male non diabetic
  • Female postmenopausal, non hormono-substituted,
  • years,
  • BMI\> 30 kg / m2
  • HOMA - IR \> 3

You may not qualify if:

  • active smoking, chronic inflammatory diseases, infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Montpellier - Lapeyronie hospital

Montpellier, 34295, France

Location

MeSH Terms

Conditions

ObesityInsulin Resistance

Interventions

Dietary Supplements

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Ariane SULTAN, Pr, MD-PHD

    Montpellier University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 9, 2015

First Posted

December 17, 2015

Study Start

October 6, 2015

Primary Completion

June 6, 2020

Study Completion

June 6, 2020

Last Updated

December 21, 2021

Record last verified: 2021-12

Locations